News
Some drugs used to reduce stomach acid may increase false positives in the colon and rectal cancer screening
A new study analyzes the influence of proton pump inhibitor drugs on the risk of false positives in an immunological fecal occult blood test, a test used to detect colorectal cancer.
Bellvitge will study the application of artificial intelligence in the treatment of Covid-19 in ICUs
The Intensive Medicine Service of the Bellvitge University Hospital (HUB) participates, through the Bellvitge Biomedical Research Institute (IDIBELL), in the European ENVISION project, which will develop an intelligent decision support system to improve the monitoring and treatment of patients with Covid-19 in ICUs.
IDIBELL celebrates the Kickoff Meeting of the projects financed by 2019 La Marató de TV3 Foundation call
Today, the Teams platform hosted the IDIBELL Kickoff Meeting La Marató 2019, aimed at all those researchers who have obtained a research project within the “Convocatòria 2019 per a l’adjudicació d’ajudes econòmiques a projectes de recerca de càncer” by La La Marató de TV3 Foundation.
New global strategy to eliminate cervical cancer
This milestone could be achieved thanks to the increased efficacy and mass administration of the vaccine as well as the modernization of screening techniques.
Today Sinergia, a new website for the dissemination of health research and innovation in L’Hospitalet, is launched
Among the activities proposed by Sinergia are a virtual escape room through the IDIBELL laboratories, family workshops and 360º visits to Bellvitge facilities.
The impact of the pandemic on people with eating disorders and obesity
Dr. Fernando Fernández-Aranda is currently the editor-in-chief of the European Eating Disorders Review, a journal that has published a special issue in October focusing on the impact of the pandemic and lockdown on patients with eating disorders and obesity. We spoke with Dr. Fernández-Aranda about this special and the reflections they have extracted.
The European project “Oncommun-ICOnnecta’t” receives two International awards
The last month this project, developed by the Catalan Institute of Oncology and IDIBELL, with the collaboration in Portugal of the Pedro Nuñez Institute, has received the awards ” Invertir me Saúde 2020″ and “HINTT Award”.
IDIBELL and its fight against Covid-19
The Covid-19 pandemic has created a big social emergency, and research progress is the only solution to face it and control it definitively. From the beginning of the crisis, IDIBELL has adapted to the new needs creating new lines of research to fight the virus and applying all the knowledge to the pandemic.
Identified a biomarker that predicts the increase in malignancy that antiangiogenic therapy can cause in kidney cancers
An IDIBELL-ICO study has identified that not only that antiangiogenic chemotherapy can induce more aggressiveness and malignancy in kidney tumors, but also, they have identified a biomarker to predict in which patients this may happen. These discoveries are another step towards making cancer therapy more personalized every day.